"Across many immuno-inflammatory diseases, patients face tradeoffs, often compromising on efficacy, safety, or convenience. We see an opportunity to change the status quo. The Phase 1b data showed KT-621 results in line with or numerically exceeding published dupilumab data at 4 weeks across every clinical endpoint evaluated in atopic dermatitis patients. KT-621 is a once-daily pill."
"About 140 million diagnosed Type 2 patients exist across the U.S., five major EU countries, and Japan, with roughly 50 million estimated to have moderate to severe disease. Yet only about 2 million are receiving advanced systemic therapies, representing a current market of about $20 billion annually. An effective oral option could pull millions of currently untreated patients into the treatment funnel."
Kymera Therapeutics reported Q4 revenue of $2.87 million and EPS of -$0.97, missing estimates, but the clinical pipeline progress represents the meaningful development. KT-621, an oral STAT6 degrader, demonstrated Phase 1b results matching or exceeding published dupilumab data across atopic dermatitis endpoints while offering once-daily oral dosing versus injectable administration. The addressable market spans 140 million diagnosed Type 2 patients across major markets, with 50 million having moderate-to-severe disease, yet only 2 million receiving advanced systemic therapies. Two Phase 2b trials are underway: BROADEN2 in atopic dermatitis targeting mid-2027 data and BREADTH in asthma with late 2027 expectations. Additionally, Kymera advanced the first IRF5-directed therapy into clinical development, representing a significant pipeline milestone.
#clinical-stage-biotech #stat6-degrader #oral-immunotherapy #type-2-inflammation #irf5-directed-therapy
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]